{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:25:33Z","timestamp":1761744333069,"version":"build-2065373602"},"reference-count":8,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.clon.2016.07.004","type":"journal-article","created":{"date-parts":[[2016,7,29]],"date-time":"2016-07-29T21:29:21Z","timestamp":1469827761000},"page":"666-667","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Response to \u2018High Risk of Neutropenia for Hormone-naive Prostate Cancer Patients Receiving STAMPEDE-style Upfront Docetaxel Chemotherapy in Usual Clinical Practice\u2019, by Tanguay et\u00a0al."],"prefix":"10.1016","volume":"28","author":[{"given":"N.D.","family":"James","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9323-1371","authenticated-orcid":false,"given":"M.R.","family":"Sydes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.W.","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.W.S.","family":"Ritchie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.K.B.","family":"Parmar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.clon.2016.07.004_bib1","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.clon.2016.03.006","article-title":"High risk of neutropenia for hormone-naive prostate cancer patients receiving STAMPEDE-style upfront docetaxel chemotherapy in usual clinical practice","volume":"28","author":"Tanguay","year":"2016","journal-title":"Clin Oncol"},{"issue":"10024","key":"10.1016\/j.clon.2016.07.004_bib2","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"James","year":"2016","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.clon.2016.07.004_bib3","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.clon.2016.07.004_bib4","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1470-2045(12)70560-0","article-title":"Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial","volume":"14","author":"Gravis","year":"2013","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.clon.2016.07.004_bib5","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S1470-2045(15)00011-X","article-title":"Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial","volume":"16","author":"Fizazi","year":"2015","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.clon.2016.07.004_bib6","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ejca.2011.10.015","article-title":"A\u00a0phase III trial of docetaxel\u2013 estramustine in high-risk localised prostate cancer: a planned analysis of response, toxicity and quality of life in the GETUG 12 trial","volume":"48","author":"Fizazi","year":"2012","journal-title":"Eur J Cancer"},{"issue":"15","key":"10.1016\/j.clon.2016.07.004_bib7","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.clon.2016.07.004_bib8","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1093\/annonc\/mdt397","article-title":"Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials","volume":"24","author":"Templeton","year":"2013","journal-title":"Ann Oncol"}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655516301820?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655516301820?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T15:42:59Z","timestamp":1760542979000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0936655516301820"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":8,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["S0936655516301820"],"URL":"https:\/\/doi.org\/10.1016\/j.clon.2016.07.004","relation":{},"ISSN":["0936-6555"],"issn-type":[{"type":"print","value":"0936-6555"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Response to \u2018High Risk of Neutropenia for Hormone-naive Prostate Cancer Patients Receiving STAMPEDE-style Upfront Docetaxel Chemotherapy in Usual Clinical Practice\u2019, by Tanguay et\u00a0al.","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clon.2016.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}